



Month	0	6	12	18	24	30	36	42	48	54	60	66	72	78	84	90	96	102	108	114	120
IFX																					
At risk	185	180	168	138	107	90	81	66	53	42	38	31	24	20	17	14	10	9	6	5	5
Persistence rate (%)	100	96.2	88.6	84.5	79.1	76.7	73.2	69.2	64.5	59.3	57.8	56.3	54.3	51.9	51.9	51.9	48.2	48.2	48.2	48.2	48.2
Lower 95% CI	100	92.2	83.1	78.4	72.2	69.3	65.3	60.8	55.4	49.6	47.9	46.1	43.7	40.8	40.8	40.8	35.7	35.7	35.7	35.7	35.7
Upper 95% CI	100	98.2	92.4	89.1	84.5	82.5	79.5	76.2	72.2	67.8	66.6	65.3	63.7	61.9	61.9	61.9	59.6	59.6	59.6	59.6	59.6
ADA																					
At risk	170	163	152	127	100	80	65	48	39	30	22	17	13	8	5	2	1				
Persistence rate (%)	100	95.9	88.2	82.8	76.1	72.7	67.8	61.8	61.8	60.1	51.6	51.6	51.6	51.6	51.6	34.4	34.4				
Lower 95% CI	100	91.6	82.4	76.1	68.6	64.7	59.2	52.4	52.4	50.3	40.1	40.1	40.1	40.1	40.1	9.8	9.8				
Upper 95% CI	100	98.0	92.2	87.7	82.1	79.2	75.0	69.9	69.9	68.6	62.0	62.0	62.0	62.0	62.0	61.2	61.2				
UST																					
At risk	65	64	61	48	32	20	9	5	3												
Persistence rate (%)	100	98.5	92.3	85.8	81.9	79.1	71.9	71.9	71.9												
Lower 95% CI	100	89.6	82.5	74.4	69.5	65.7	51.4	51.4	51.4												
Upper 95% CI	100	99.8	96.7	92.3	89.6	87.8	85.0	85.0	85.0												

Supplementary Fig. 2. Persistence of a first-line biologic in patients with newly diagnosed Crohn's disease (biologic group) for TNF- α inhibitors (IFX, ADA) and interleukin (IL)-12/IL-23 antibody (UST). TNF, tumor necrosis factor; IFX, infliximab; ADA, adalimumab; UST, ustekinumab; CI, confidence interval.